[Retracted] Correlation Analysis of DNA Methylation in the von Willebrand Factor Promoter Region and the Risk of Unexplained Recurrent Hemophilia: Systematic Review and Meta-Analysis

Table 1

Basic clinical features of 12 kinds of literature were included in our study.

Study	Age	Gender (male) (%)	Result indicators	Experimental group	Control group	NOS score	Research type
Van Moort et al. 2020 [11]	55.71 ± 1.2	41.25	Case fatality rate, adverse events, etc.	42/59	32/59	7	RCT
Neufeld et al. 2018 [12]	57.65 ± 3.4	59.12	Case fatality rate, adverse events, etc.	56/78	45/78	9	RCT
Lalezari et al. 2014 [13]	43.12 ± 4.5	45.72	Case fatality rate, adverse events, etc.	48/63	42/68	8	RCT
Kessler et al. 2011 [14]	17.15 ± 4.5	44.12	Case fatality rate, adverse events, etc.	107/120	89/120	8	RCT
Gill et al. 2015 [15]	42.85 ± 8.4	51.89	Case fatality rate, adverse events, etc.	122/192	105/192	8	RCT
Mannucci et al. 2013 [16]	64.36 ± 1.2	53.45	Case fatality rate, adverse events, etc.	28/32	22/32	7	RCT
Skotnicki et al. 2016 [17]	32.62 ± 2.2	58.10	Case fatality rate, adverse events, etc.	48/65	40/65	9	RCT
Mannucci et al. 1992 [18]	42.61 ± 3.0	48.75	Case fatality rate, adverse events, etc.	15/18	12/18	9	RCT
Nemes et al. 2007 [19]	57.25 ± 4.5	59.23	Case fatality rate, adverse events, etc.	600/623	567/623	7	RCT
Lethagen et al. 2000 [20]	46.22 ± 5.2	56.22	Case fatality rate, adverse events, etc.	25/30	23/30	7	RCT
Peyvandi et al. 2019 [21]	51.35 ± 2.1	43.16	Case fatality rate, adverse events, etc.	48/52	125/172	8	RCT
Tosetto et al. 2000 [22]	51.25 ± 1.1	46.34	Case fatality rate, adverse events, etc.	28/32	21/32	8	RCT